News & Updates
Filter by Specialty:

Personalized faricimab dosing shows durable efficacy in nAMD
30 Jul 2024
byStephen Padilla
A treat-and-extend personalized treatment with faricimab based on disease activity results in sustained gains in vision or anatomic outcomes through 2 years in patients with neovascular age-related macular degeneration (nAMD), reports a study. Moreover, nearly four in five (80 percent) patients have achieved extended dosing intervals of 12 weeks or more.
Personalized faricimab dosing shows durable efficacy in nAMD
30 Jul 2024
Glaucoma in patients with diabetes ups risk of diabetic retinopathy
06 Jul 2024
Diabetic patients with primary open-angle glaucoma (POAG) are at greater risk of developing diabetic retinopathy (DR), reveals a study, noting the need for screening and comprehensive management in glaucomatous patients with diabetes to reduce the risk of DR.